Summit Therapeutics Inc. (SMMT) News
Follow Summit Therapeutics Inc. (SMMT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 63 public stories across 23 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Summit Therapeutics Reports Third-Quarter Financial Results and Operational Progress
Summit Therapeutics reported financial results and operational progress for the third quarter and nine months ended September 30, 2026.
EQUITY | Nov 04, 2026, 09:36 PM UTC
M
Summit Therapeutics Q3'26 Earnings Preview
Summit Therapeutics is scheduled to report Q3'26 results on November 11. Revenue and EPS estimates were provided, but their amounts are omitted here.
EQUITY | Nov 04, 2026, 12:00 PM UTC
M
Ivonescimab Shows Overall Survival Benefit in Phase III BTC Trial
Summit Therapeutics said partner Akeso’s Phase III HARMONi-GI1 trial found ivonescimab plus chemotherapy improved overall survival versus durvalumab plus chemotherapy in first-line advanced biliary tract cancer. The over
EQUITY | Oct 25, 2026, 03:52 PM UTC
M
Treasury Proposes Bans on U.S. Investment in Chinese Biotech, AI
The U.S. Treasury Department proposed restrictions on American investment in Chinese biotech, artificial intelligence and advanced memory chips. The proposal could cut off a source of new drugs for the pharmaceutical ind
REGULATION | Oct 23, 2026, 08:09 AM UTC
L
Summit Therapeutics Opens Phase II Study of Ivonescimab Regimens
The global Phase II study will evaluate ivonescimab-based regimens in advanced clear cell renal cell carcinoma.
EQUITY | Oct 19, 2026, 11:05 AM UTC
H
Stock Market Today: S&P 500, Russell 2000 Fall as 30-Year Yield Hits 5.7%
U.S. stocks slipped by midday Wednesday as a sharp selloff in industrials weighed on the Dow Jones and small caps, while healthcare provided a rare pocket of strength. The S&P 500 fell 0.4% to 7,788, while the Dow Jones
LIVE | Oct 07, 2026, 04:53 PM UTC
M
AstraZeneca completes $2 billion equity investment in Summit Therapeutics
AstraZeneca completed a $2 billion equity investment in Summit Therapeutics.
MNA | Oct 05, 2026, 11:04 AM UTC
H
Summit Therapeutics Closes $2B Equity Investment From AstraZeneca
Summit Therapeutics Inc. has closed a $2.0 billion equity investment from AstraZeneca, structured as preferred stock convertible into common stock at an implied price of $18.36 per share. The funding will support the dev
EQUITY | Oct 05, 2026, 11:01 AM UTC
L
Key facts: SMMT Seeks Financing; Shares Jump on AstraZeneca Pact
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.
EQUITY | Sep 30, 2026, 07:02 AM UTC
L
Summit Therapeutics Price Target Raised to $43.00/Share From $40.00 by Citigroup
Ratings actions from Benzinga
NEWS | Sep 29, 2026, 06:02 PM UTC
L
AstraZeneca Stock Slips as $2 Billion Summit Stake Deepens Oncology
AstraZeneca NYSE:AZN, the oncology and biopharmaceutical company, agreed to invest $2 billion in Summit Therapeutics to test new cancer drug combinations. Its shares were down about 0.7% at $164.95 at 9.55am EST time on
EQUITY | Sep 29, 2026, 05:18 PM UTC
H
FTSE 100 hits two-week low as energy stocks slide
London's FTSE 100 slipped to a two-week low on Tuesday, dragged down by heavyweight energy stocks as oil prices retreated, while British American Tobacco fell after issuing downbeat guidance.The blue-chip FTSE 100 index
COMMODITIES | Sep 29, 2026, 04:25 PM UTC
L
Summit Stock Jumps 17% on $2 Billion AstraZeneca Investment
Summit Therapeutics NASDAQ:SMMT, which holds rights to the cancer drug ivonescimab in major markets outside China, rose 16.99% in premarket after AstraZeneca NYSE:AZN agreed to invest $2 billion in newly issued Summit eq
GEOPOLITICS | Sep 29, 2026, 04:08 PM UTC
M
Wall St to open higher on oil retreat, tech optimism
By Shashwat Chauhan and Tharuniyaa LakshmiWall Street's main indexes were set to open higher on Tuesday, helped by a pullback in oil prices, while media reports of the details about Anthropic's public offering also bolst
COMMODITIES | Sep 29, 2026, 01:03 PM UTC
M
US stock futures tick higher as tech steadies though oil, yields stay high
By Shashwat Chauhan and Tharuniyaa LakshmiUS stock index futures inched higher on Tuesday as some technology stocks found footing, though risk sentiment remained in check as the ongoing Middle East conflict kept oil pric
COMMODITIES | Sep 29, 2026, 11:48 AM UTC
L
AstraZeneca Makes Smart Move With Summit Therapeutics Deal — Market Talk
AstraZeneca's deal with Summit Therapeutics looks like a strategically smart move for the U.K. drugmaker, which adds combination options for its portfolio while keeping risk exposure low, analysts at Jefferies say in a r
NEWS | Sep 29, 2026, 10:34 AM UTC
L
Summit Therapeutics Raises $2.0 Billion in Convertible Preferred Private Placement With AstraZeneca
Summit Therapeutics announced a $2.0 billion private placement through a securities purchase agreement with AstraZeneca for Class A Convertible Preferred Stock. The deal covers 108,955.3686 preferred shares at $18,356.14
EQUITY | Sep 29, 2026, 10:13 AM UTC
L
Summit soars after $2 billion investment from AstraZeneca for cancer therapies
Summit Therapeutics' NASDAQ:SMMT shares rose 23% in premarket trading on Tuesday after the drugmaker said AstraZeneca LSE:AZN would invest $2 billion in the company to test cancer treatments together.UK-listed shares of
EQUITY | Sep 29, 2026, 10:11 AM UTC
L
AstraZeneca's Summit Therapeutics Investment Looks Like Win-Win for Both — Market Talk
AstraZeneca's $2 billion investment in Summit Therapeutics works for both companies, UBS analysts say in a research note. For Summit, this is potentially a best-case scenario that provides external validation of its lead
NEWS | Sep 29, 2026, 10:11 AM UTC
H
US stock futures flat as tech bounce meets crude-driven caution
US stock index futures traded sideways on Tuesday, though tech and AI-linked stocks ticked higher, as rising crude oil prices and steep bond yields kept risk appetite in check over the lack of progress in US-Iran peace t
COMMODITIES | Sep 29, 2026, 09:50 AM UTC
L
FTSE 100 rises as AstraZeneca lifts healthcare sector
London's FTSE 100 rose on Tuesday, lifted by pharmaceutical stocks after AstraZeneca agreed to take a $2 billion stake in Summit Therapeutics to advance cancer research.The blue-chip FTSE 100 index CURRENCYCOM:UK100 rose
NEWS | Sep 29, 2026, 09:47 AM UTC
H
Nasdaq Futures Tread Water After Monday Rout: MU, NVTS, NVO, KOD, SMMT, ASTS Stocks In Focus
U.S. stock futures were subdued early Tuesday as rising Treasury yields and ongoing artificial intelligence safety concerns weighed on market sentiment. Meanwhile, President Donald Trump and House Speaker Mike Johnson ar
GEOPOLITICS | Sep 29, 2026, 08:32 AM UTC
L
Astrazeneca to invest $2bn in Summit Therapeutics, AG Barr backs FY expectations
STOCKS TO WATCHAstrazeneca will invest $2bn in US biopharma Summit Therapeutics, the British drugs giant confirmed on Tuesday. Under the terms of the deal, Astrazeneca will buy newly-issued equity in the New York-listed
NEWS | Sep 29, 2026, 06:43 AM UTC
L
AstraZeneca to invest $2bn in Summit Therapeutics
Under the terms of the deal, AstraZeneca will buy newly-issued equity in the New York-listed oncology specialist, giving it rights equivalent to around 12% of Summit’s common stock, or around 10.6% on a fully diluted bas
EQUITY | Sep 29, 2026, 06:43 AM UTC
L
AstraZeneca Broadens Oncology Portfolio Through Summit Deal — Market Talk
AstraZeneca's agreement with Summit Therapeutics will help the U.K. drugmaker broaden its immuno-oncology portfolio without going all-in, RBC Capital Markets analysts say in a research note. AstraZeneca is investing $2 b
NEWS | Sep 29, 2026, 05:49 AM UTC
L
SMMT Stock Soars After-Hours: Did AstraZeneca Just End Summit’s Cash Scare?
Shares of Summit Therapeutics (SMMT) jumped in after-hours trading on Monday after AstraZeneca agreed to put $2 billion into the cancer-drug developer, sending the stock as much as 19% above its regular close.AZN-SMMT De
EQUITY | Sep 28, 2026, 11:36 PM UTC
L
Summit Shares Surge on $2 Billion AstraZeneca Investment — WSJ
By Xavier MartinezShares of Miami-based Summit Therapeutics surged about 17% in after-hours trading Monday after AstraZeneca announced it would invest $2 billion in the cancer-drug developer. AstraZeneca's stake would eq
EQUITY | Sep 28, 2026, 11:29 PM UTC
L
Summit Therapeutics Stock Surges After AstraZeneca Reveals $2 Billion Investment — Barrons.com
By Evie LiuSummit Therapeutics stock jumped about 15% in after-hours trading Monday after pharmaceutical giant AstraZeneca announced a $2 billion investment in the cancer-drug developer, alongside an agreement to collabo
EQUITY | Sep 28, 2026, 10:27 PM UTC
L
AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs
By Elias SchisgallAstraZeneca is investing $2 billion into Summit Therapeutics as part of an expanded partnership between the two companies.Summit said Monday that AstraZeneca will buy $2 billion of convertible preferred
EQUITY | Sep 28, 2026, 10:25 PM UTC
L
AstraZeneca to Invest $2B in Summit Therapeutics, Collaborate on Cancer Drugs
By Elias SchisgallAstraZeneca is investing $2 billion into Summit Therapeutics as part of an expanded partnership between the two companies.Summit said Monday that AstraZeneca will buy $2 billion of convertible preferred
EQUITY | Sep 28, 2026, 10:10 PM UTC
L
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up
Summit Therapeutics NASDAQ:SMMT said on Monday that British drugmaker AstraZeneca LSE:AZN would invest $2 billion in the company and collaborate on a series of studies testing their cancer treatments together.Summit's sh
EQUITY | Sep 28, 2026, 10:09 PM UTC
L
Summit Therapeutics Inc. (SMMT) Gets $2B AZ Equity Investment, Inks Clinical Collaboration
Summit Therapeutics will receive a $2.0B AstraZeneca equity investment in convertible preferred shares at an implied $18.36, subject to closing, and entered a clinical collaboration on ivonescimab with sone-ve and plans
EQUITY | Sep 28, 2026, 09:30 PM UTC
L
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
Summit Therapeutics Inc. (NASDAQ:SMMT) today announced key developments important to the company’s progress towards achieving its goal of making a significant difference in the lives of patients with cancer. Specifically
NEWS | Sep 28, 2026, 09:30 PM UTC
L
US drugmakers turn to China for licensing deals
Merck NYSE:MRK on Monday agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global rights to an experimental cancer drug, making it the latest US drugmaker to license China-developed medicines.
GEOPOLITICS | Sep 28, 2026, 02:31 PM UTC
L
Weekly Recap: BTC Phase III OS at ESMO 2026 and ivonescimab China approval
Summit Therapeutics Inc (NASDAQ:SMMT) said Phase III BTC topline data showing overall survival superiority will be presented at ESMO 2026 while the company advances licensed ivonescimab, a dual—action bispecific antibody
GEOPOLITICS | Sep 28, 2026, 11:05 AM UTC
L
Summit Therapeutics presents updated HARMONi OS data showing consistent survival benefit with ivonescimab; BLA PDUFA Nov 14, 2026
Summit Therapeutics announced updated HARMONi Phase III overall survival results showing a consistent OS benefit for ivonescimab plus chemotherapy versus placebo plus chemotherapy.Key Highlights:Original SEC Filing: Summ
REGULATION | Sep 15, 2026, 12:55 PM UTC
L
Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients
Summit Therapeutics Inc. (Nasdaq: SMMT) announced that updated overall survival (OS) results from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antib
NEWS | Sep 15, 2026, 10:00 AM UTC
L
Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial
Summit Therapeutics NASDAQ:SMMT on Sunday said ivonescimab significantly extended survival compared with Merck’s NYSE:MRK Keytruda in a late-stage lung cancer trial conducted by its partner Akeso OTC:AKESF in China.Ivone
GEOPOLITICS | Sep 13, 2026, 05:23 PM UTC
L
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China
Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced that updated data, including overall survival (OS), from the randomized, double-blind Phase III HARMONi-2 trial featuring the nove
GEOPOLITICS | Sep 13, 2026, 11:00 AM UTC
L
Jefferies upgrades Summit Therapeutics to Buy from Hold
Benzinga (via TradingView News) reports Jefferies raised its rating on Summit Therapeutics from Hold to Buy.
EQUITY | Sep 09, 2026, 09:32 PM UTC
L
UK new car registrations rise 13.7% year-on-year to 94,236
Society of Motor Manufacturers and Traders data shows UK new car registrations up 13.7% year-on-year to 94,236 units, the ninth straight month of growth. Private registrations rose 19.0%.
EQUITY | Sep 04, 2026, 12:06 PM UTC
M
Summit Therapeutics stock jumps as ivonescimab extends survival in China
Shares of Summit Therapeutics rose more than 12% Thursday morning after the company said ivonescimab is extending survival in a Chinese lung cancer study, lifting the stock to $16.46.
EQUITY | Sep 03, 2026, 04:00 PM UTC
M
Summit notes Akeso reported OS benefit in HARMONi-2
Summit Therapeutics said partner Akeso reported ivonescimab achieved a statistically significant overall survival benefit versus pembrolizumab in the Phase III HARMONi-2 study.
REGULATION | Sep 03, 2026, 01:23 PM UTC
M
SMMT ivonescimab shows statistically significant OS benefit vs pembrolizumab
SMMT reports ivonescimab monotherapy showed a statistically significant overall survival benefit versus pembrolizumab monotherapy in PD-L1-positive advanced NSCLC in the HARMONi-2 study.
GEOPOLITICS | Sep 02, 2026, 09:42 PM UTC
M
HARMONi-2 study shows OS benefit for ivonescimab monotherapy vs pembrolizumab
Summit Therapeutics said Akeso announced positive overall survival results from the Phase III HARMONi-2 randomized, double-blind study comparing ivonescimab and pembrolizumab monotherapy in PD-L1-positive advanced NSCLC.
GEOPOLITICS | Sep 02, 2026, 09:41 PM UTC
L
Summit trials gain credibility after Akeso Phase 3 data, Guggenheim says
Guggenheim said Summit’s global lung cancer trials gained credibility following Akeso’s Phase 3 data, per TradingView News.
EQUITY | Aug 26, 2026, 05:51 PM UTC
L
Summit Therapeutics flags OS superiority for ivonescimab Phase III
TradingView News reports Summit Therapeutics says its ivonescimab regimen shows OS superiority in Phase III HARMONi-GI1.
EQUITY | Aug 26, 2026, 01:24 PM UTC
M
Ivonescimab plus chemotherapy reports overall survival benefit in trial
SMMT said Ivonescimab plus chemotherapy showed a statistically significant overall survival benefit versus durvalumab plus chemotherapy in first-line advanced biliary tract cancer in a single-region trial in China.
GEOPOLITICS | Aug 25, 2026, 10:08 PM UTC
L
SMMT publishes Phase III HARMONi analysis in Lancet Oncology
SMMT publishes primary analysis results from its global Phase III HARMONi study of ivonescimab plus chemotherapy in The Lancet Oncology.
EQUITY | Aug 25, 2026, 11:07 AM UTC
H
SMMT: Ivonescimab Approved in China
SMMT's Ivonescimab is approved in China for first-line treatment of squamous non-small cell lung cancer
EQUITY | Aug 12, 2026, 01:26 PM UTC
M
Multiple Stocks Upgraded
Several stocks receive upgrades from various analysts
EQUITY | Aug 12, 2026, 10:47 AM UTC
M
Summit Therapeutics Expands Ivonescimab Program
Summit Therapeutics starts new cancer study
EQUITY | Aug 05, 2026, 11:08 AM UTC
H
Alpha Buying: When a CEO Spends $5 Million on His Own Stock, Pay Attention
Corporate executives say optimistic things about their companies every day. They appear on earnings calls, investor presentations and financial television programs to explain why the latest disappointing quarter is merel
EARNINGS | Jul 24, 2026, 07:29 PM UTC
H
Deckers Outdoor, Summit Therapeutics, Robert Half And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Friday. Shares of Deckers Outdoor Cor p (NYSE: DECK ) fell sharply in pre-market trading after the company reported first-qua
EARNINGS | Jul 24, 2026, 12:04 PM UTC
H
Closing Bell Movers: Intel up 4% on Q2 earnings beat
Mega-cap Tech weighed heavily on sentiment in Thursday's trading as elevated capex plans by Alphabet (GOOGL) and Tesla (TSLA) worried investors. Parent of Google fell 7% to trade at a 3-month lows, while Tesla shed 15%,
RATES | Jul 24, 2026, 12:02 AM UTC
L
SMMT Summit Therapeutics - to offer and sell common stock up to $380M aggregate through sales agent - SEC filing
SMMT Summit Therapeutics - to offer and sell common stock up to $380M aggregate through sales agent - SEC filing
REGULATION | Jul 23, 2026, 08:35 PM UTC
L
Summit Therapeutics reports Q2 EPS (28c), consensus (21c)
"The clinical...
EQUITY | Jul 23, 2026, 08:10 PM UTC
L
RHI -10.4%, FIX -3.6%, SMMT -3%, SKYW -2.7%, SCHL -2.5% after results
RHI -10.4%, FIX -3.6%, SMMT -3%, SKYW -2.7%, SCHL -2.5% after results
EQUITY | Jul 23, 2026, 08:10 PM UTC
L
SMMT Summit Therapeutics RESULTS: Q2, Q2 EPS $-0.28, Q2 Net Income $-215.7M, Q2 operating expenses $220.5M
SMMT Summit Therapeutics RESULTS: Q2, Q2 EPS $-0.28, Q2 Net Income $-215.7M, Q2 operating expenses $220.5M
EARNINGS | Jul 23, 2026, 08:06 PM UTC
H
Summit Therapeutics options imply 6.5% move in share price post-earnings
Summit Therapeutics options imply 6.5% move in share price post-earnings
EARNINGS | Jul 23, 2026, 05:50 PM UTC